MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells

The therapeutic options for advanced gastric cancer are still limited. Several drugs targeting the epidermal growth factor receptor family have been developed. So far, the HER2 antibody trastuzumab is the only drug targeting the HER-family that is available to gastric cancer patients. The pan-HER in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebert, Karolin, Mattes, Julian, Kunzke, Thomas, Zwingenberger, Gwen, Luber, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763200/
https://www.ncbi.nlm.nih.gov/pubmed/31557260
http://dx.doi.org/10.1371/journal.pone.0223225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763200/
https://www.ncbi.nlm.nih.gov/pubmed/31557260
http://dx.doi.org/10.1371/journal.pone.0223225

Ejemplares similares